Cardiol Therapeutics Inc. (TSE:CRDL - Get Free Report)'s share price shot up 2.1% on Thursday . The stock traded as high as C$1.97 and last traded at C$1.95. 48,665 shares were traded during trading, a decline of 35% from the average session volume of 75,373 shares. The stock had previously closed at C$1.91.
Cardiol Therapeutics Stock Performance
The company's 50-day moving average price is C$1.59 and its two-hundred day moving average price is C$1.71. The company has a debt-to-equity ratio of 1.59, a quick ratio of 6.84 and a current ratio of 2.49. The stock has a market cap of C$160.15 million, a PE ratio of -3.79 and a beta of 0.70.
Cardiol Therapeutics Company Profile
(
Get Free Report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Read More
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
